PE20240802A1 - Anticuerpos multiespecificos con especificidad para il-4r e il-31 - Google Patents
Anticuerpos multiespecificos con especificidad para il-4r e il-31Info
- Publication number
- PE20240802A1 PE20240802A1 PE2023001896A PE2023001896A PE20240802A1 PE 20240802 A1 PE20240802 A1 PE 20240802A1 PE 2023001896 A PE2023001896 A PE 2023001896A PE 2023001896 A PE2023001896 A PE 2023001896A PE 20240802 A1 PE20240802 A1 PE 20240802A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- sequence
- multispecific antibody
- sequences
- acids
- Prior art date
Links
- 108040006852 interleukin-4 receptor activity proteins Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- -1 acids nucleic acids Chemical class 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a un anticuerpo multiespecifico con especificidad para IL-4R e IL-31, que comprende: a) uno o dos dominios de union, que se unen especificamente a IL-4R (IL4R-BD), y b) uno o dos dominios de union, que se unen especificamente a IL-31 (IL31-BD), en el que el anticuerpo multiespecifico comprende una region Fc de inmunoglobulina; cada uno de dichos IL4R-BD comprende: la secuencia de HCDR1 de SEQ ID NO: 1, las secuencias HCDR2 de SEQ ID NO: 2, la secuencia de HCDR3 de SEQ ID NO: 3, la secuencia de LCDR1 de SEQ ID NO: 7, la secuencia de LCDR2 de SEQ ID NO: 8, y las secuencias LCDR3 de SEQ ID NO: 9; y cada uno de dichos IL31-BD comprende: la secuencia de HCDR1 de SEQ ID NO: 12, la secuencia de HCDR2 de SEQ ID NO: 13, las secuencias HCDR3 de SEQ ID NO: 14, la secuencia de LCDR1 de SEQ ID NO: 17 o 18, la secuencia de LCDR2 de SEQ ID NO: 19, y las secuencias LCDR3 de SEQ ID NO: 20. Tambien se refiere a uno o dos acidos nucleicos que codifican dicho anticuerpo multiespecifico, uno o dos vectores que comprenden dichos acidos nucleicos, una celula huesped que comprende dichos acidos vectores, un procedimiento de produccion de dicho anticuerpo multiespecifico, una composicion farmaceutica que comprende dicho anticuerpo multiespecifico, y su uso en el tratamiento de enfermedades alergicas, inflamatorias y autoinmunes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20216957.9A EP4019547A1 (en) | 2020-12-23 | 2020-12-23 | Multispecific antibodies having specificity for il-4r and il-31 |
| PCT/EP2021/087561 WO2022136669A1 (en) | 2020-12-23 | 2021-12-23 | Multispecific antibodies having specificity for il-4r and il-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240802A1 true PE20240802A1 (es) | 2024-04-18 |
Family
ID=73857084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001896A PE20240802A1 (es) | 2020-12-23 | 2021-12-23 | Anticuerpos multiespecificos con especificidad para il-4r e il-31 |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP4019547A1 (es) |
| JP (1) | JP2024501811A (es) |
| KR (1) | KR20230125238A (es) |
| CN (3) | CN116940596A (es) |
| AU (1) | AU2021405058A1 (es) |
| CA (1) | CA3205036A1 (es) |
| CL (1) | CL2023001888A1 (es) |
| CO (1) | CO2023009615A2 (es) |
| CR (1) | CR20230309A (es) |
| DO (1) | DOP2023000130A (es) |
| EC (1) | ECSP23053070A (es) |
| IL (1) | IL303174A (es) |
| MX (1) | MX2023007533A (es) |
| PE (1) | PE20240802A1 (es) |
| TW (1) | TW202241966A (es) |
| WO (1) | WO2022136669A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3227014A1 (en) | 2021-08-23 | 2023-03-02 | Ashish Bansal | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CA3241374A1 (en) | 2021-12-30 | 2023-07-06 | Gregory GEBA | Methods for attenuating atopic march by administering an il-4/il-13 antagonist |
| WO2024011251A1 (en) | 2022-07-08 | 2024-01-11 | Regeneron Pharmaceuticals, Inc. | Methods for treating eosinophilic esophagitis in pediatric by administering an il-4r antagonist |
| WO2024061279A1 (en) * | 2022-09-22 | 2024-03-28 | Biosion Inc. | Recombinant bispecific antibodies targeting tslp and il4r |
| US20240141051A1 (en) | 2022-11-01 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
| WO2024112935A1 (en) | 2022-11-23 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Methods for improving bone growth by administering an il-4r antagonist |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| DE3856559T2 (de) | 1987-05-21 | 2004-04-29 | Micromet Ag | Multifunktionelle Proteine mit vorbestimmter Zielsetzung |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5766886A (en) | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
| DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| EP2759549B1 (en) * | 2006-09-01 | 2015-08-19 | ZymoGenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
| EP3889181B1 (en) | 2012-09-07 | 2024-04-24 | Regeneron Pharmaceuticals, Inc. | An il-4r antagonist antibody for use in treating atopic dermatitis by administering |
| EP3459968A1 (en) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Novel stable antibody variable domain framework combinations |
| CN110746507B (zh) * | 2018-12-25 | 2020-06-26 | 江苏荃信生物医药有限公司 | 抗人白介素4受体α单克隆抗体及其应用 |
-
2020
- 2020-12-23 EP EP20216957.9A patent/EP4019547A1/en not_active Ceased
-
2021
- 2021-12-23 CR CR20230309A patent/CR20230309A/es unknown
- 2021-12-23 AU AU2021405058A patent/AU2021405058A1/en active Pending
- 2021-12-23 WO PCT/EP2021/087561 patent/WO2022136669A1/en active Application Filing
- 2021-12-23 PE PE2023001896A patent/PE20240802A1/es unknown
- 2021-12-23 CN CN202180094172.8A patent/CN116940596A/zh active Pending
- 2021-12-23 CN CN202180085945.6A patent/CN116888151A/zh active Pending
- 2021-12-23 CA CA3205036A patent/CA3205036A1/en active Pending
- 2021-12-23 TW TW110148468A patent/TW202241966A/zh unknown
- 2021-12-23 MX MX2023007533A patent/MX2023007533A/es unknown
- 2021-12-23 JP JP2023537629A patent/JP2024501811A/ja active Pending
- 2021-12-23 KR KR1020237024442A patent/KR20230125238A/ko unknown
- 2021-12-23 IL IL303174A patent/IL303174A/en unknown
- 2021-12-23 CN CN202180094017.6A patent/CN116848134A/zh active Pending
- 2021-12-23 EP EP21847487.2A patent/EP4267613A1/en active Pending
-
2023
- 2023-06-22 CL CL2023001888A patent/CL2023001888A1/es unknown
- 2023-06-23 DO DO2023000130A patent/DOP2023000130A/es unknown
- 2023-07-14 EC ECSENADI202353070A patent/ECSP23053070A/es unknown
- 2023-07-19 CO CONC2023/0009615A patent/CO2023009615A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4267613A1 (en) | 2023-11-01 |
| CL2023001888A1 (es) | 2023-12-15 |
| MX2023007533A (es) | 2023-09-19 |
| ECSP23053070A (es) | 2023-08-31 |
| EP4019547A1 (en) | 2022-06-29 |
| TW202241966A (zh) | 2022-11-01 |
| CA3205036A1 (en) | 2022-06-30 |
| AU2021405058A1 (en) | 2023-06-29 |
| CN116888151A (zh) | 2023-10-13 |
| KR20230125238A (ko) | 2023-08-29 |
| CN116848134A (zh) | 2023-10-03 |
| JP2024501811A (ja) | 2024-01-16 |
| CN116940596A (zh) | 2023-10-24 |
| CO2023009615A2 (es) | 2023-08-28 |
| CR20230309A (es) | 2023-10-09 |
| DOP2023000130A (es) | 2023-09-15 |
| IL303174A (en) | 2023-07-01 |
| WO2022136669A1 (en) | 2022-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240802A1 (es) | Anticuerpos multiespecificos con especificidad para il-4r e il-31 | |
| JP2022177090A5 (es) | ||
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
| PE20210180A1 (es) | Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20180604A1 (es) | Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana) | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR105026A1 (es) | ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO | |
| PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
| NZ731735A (en) | Anti-pd-1 antibodies and methods of use thereof | |
| JP2017525343A5 (es) | ||
| PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
| AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
| AR103713A1 (es) | Anticuerpos contra tau y sus usos | |
| SI2970447T1 (en) | PROTITELES AGAINST PAN-ELR + CXC KEMOCIN | |
| AR104906A1 (es) | Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos | |
| JP2016520595A5 (es) | ||
| PE20141706A1 (es) | Anticuerpos de union a trombina y usos del mismo | |
| RU2017134043A (ru) | Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью |